3-28-05

Ifie)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

: 10/680,076

Applicant:

: Bell et al.

Filed:

October 6, 2003

Group Art Unit

1614

Examiner:

: Not assigned

For:

TRIAZA COMPOUND

R

REGULATORY AGENTS

Docket No.

: 36-02

Customer No.

: 23713

0n 3 (25 /0

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 EV 569 066 402 US

Confirmation No.: 9942

L Murray

INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The Examiner is respectfully requested to consider the references, copies enclosed, which may qualify as prior art. For the Examiner's convenience, the references are listed on the attached Patent and Trademark Office form PTO-1449. Pursuant to the Waiver published in the Official Gazette on August 5, 2003, because this application was filed after June 30, 2003, copies of cited U.S. patents are not included, but will be provided upon request.

JP08-27129 is in Japanese. Applicants do not have a translation of this document. An English abstract is provided to indicate the relevance of the document. Applicants also direct the Examiner to chemical formula and drawings of the document which provide additional insight into the relevance of the document.

Where the month of a reference is not listed, the year of publication is sufficiently earlier than the effective U.S. filing date so that the particular month of publication is not an issue.

References known to the applicants have been listed on PTO-1449. That information is cited in a spirit of forthrightness and cooperation to enable the applicants

to obtain that measure of protection for the invention to which there is entitlement. However, no representation is made that the listed art actually qualifies as prior art under the patent statute and the mere use of PTO-1449 is not an admission that all listed references are prior art. No representation is made that applicants know of the best art.

Respectfully submitted,

Sally A. Syllivan Reg. No. 32,064

GREENLEE, WINNER AND SULLIVAN, P.C. 5370 Manhattan Circle, Suite 201, Boulder, CO 80303 Telephone: (303) 499-8080; Facsimile: (303) 499-8089

Attorney Docket No. 36-02

lem:March 25, 2005

Substitute for form 1449/PTO, based on PTO/SB/08A 200 08B	Application Number	10/680,076
	Filing Date	October 6, 2003
INFORMATION DISCLOSURE	\First Named Inventor	Bell et al.
STATEMENT BY APPLIGANTA,	Art Unit	1614
₹ 5005 E	Examiner Name	Not assigned
F003	Attorney Docket Number	36-02

PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Document Number (US-)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)
		6,342,492	01/29/02	Bell	
		6,335,339	01/01/02	Arenas et al.	
		5,663,161	09/02/97	Bell	
		5,565,562	10/15/96	Parker et al.	
		2002/0019423	02/14/02	Bell	

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Foreign Patent Document Number (include WIPO country code)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	T²
		WO96/025167	08/22/96			
		JP 08-27129	01/30/96			

NON-PATENT LITERATURE DOCUMENTS

Examiner Cite		REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Bell, T.W. et al. (March 2002), "Specific CD4 Down-modulating Compounds with Potent Anti-HIV and HHV-7 Activity," Abstract, 15 th Intl. Conference on Antiviral Research, Prague, Czech Republic, March 17-21, 2002	
		Chieco-Bianchi, L. et al. (1989), "CD4 modulation and inhibition of HIV-1 infectivity induced by monosialoganglioside GM1 in vitro," AIDS 3:501-507	
		Chowdhury, I.H. et al. (1990), "The Phorbol Ester TPA Strongly Inhibits HIV-1-induced Synctia Formation but Enhances Virus Production: Possible Involvement of Protein Kinase C Pathway," Virology 176 :126-132	
		Hoffman, T.L. et al. (1990), "Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein," Proc. Natl. Acad. Sci. USA 96 :6359-6364	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here or "x" if English language Translation is attached.

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B **Application Number** 10/680,076 October 6, 2003 Filing Date INFORMATION DISCLOSURE First Named Inventor Bell et al. STATEMENT BY APPLICANT Art Unit 1614 Not assigned Examiner Name Attorney Docket Number 36-02

Cite No.1	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	Kabat, D. et al. (1994), "Differences in CD4 Dependence for Infectivity of Laboratory-Adapted and Primary Patient Isolates of Human Immunodeficiency Virus Type 1." J. Virol. 68 :2570-2577	
	Kolchinski, P. et al. (March 2001), "Increased Neutralization Sensitivity of CD4-Independent Human Immunodeficiency Virus Variants," J. Virol. 75 :2041-2050	
	Layne, S.P. et al. (1990), "HIV requires multiple gp120 molecules for CD4 mediated infection," Nature 346 :277-279	
	Neudorf, S. et al. (1989), "Expression of the CD4 Molecule of Acute Nonlymphocytic Leukemia (ANLL) Cell Lines," J. Clin. Lab. Anal. 3:312-315	
	Platt, E.J. et al. (1997), "Infectious Properties of Human Immunodeficiency Virus Type 1 Mutants with Distinct Affinities for the CD4 Receptor," J. Virol. 61 :883-890	
	Schols, D. et al. (1989), "Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor," Proc. Natl. Acad. Sci. USA 86 :3322-3326	
-	Vermeire, K. et al. (January 2003), "The Anti-HIV Potency of Cyclotriazadisulfonamide Analogs is Directly Correlated with Their Ability to Down-Modulate the CD4 Receptor,"Mol. Pharmacol. 63 :203-210	
	Vermeire, K. et al. (October 2002), "CADA Inhibits Human Immunodeficiency Virus and Human Herpesvirus 7 Replication by Down-modulation of the Cellular CD4 Receptor," Virology 302 : 342-353	
	Zhang, Y. et al. (1999), "Selective activity of various antiviral compounds against HHV-7 infection," Antiviral Res. 43 :23-35	
		Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Kabat, D. et al. (1994), "Differences in CD4 Dependence for Infectivity of Laboratory-Adapted and Primary Patient Isolates of Human Immunodeficiency Virus Type 1," J. Virol. 68:2570-2577 Kolchinski, P. et al. (March 2001), "Increased Neutralization Sensitivity of CD4-Independent Human Immunodeficiency Virus Variants," J. Virol. 75:2041-2050 Layne, S.P. et al. (1990), "HIV requires multiple gp120 molecules for CD4 mediated infection," Nature 346:277-279 Neudorf, S. et al. (1989), "Expression of the CD4 Molecule of Acute Nonlymphocytic Leukemia (ANLL) Cell Lines," J. Clin. Lab. Anal. 3:312-315 Platt, E.J. et al. (1997), "Infectious Properties of Human Immunodeficiency Virus Type 1 Mutants with Distinct Affinities for the CD4 Receptor," J. Virol. 61:883-890 Schols, D. et al. (1989), "Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor," Proc. Natl. Acad. Sci. USA 86:3322-3326 Vermeire, K. et al. (January 2003), "The Anti-HIV Potency of Cyclotriazadisulfonamide Analogs is Directly Correlated with Their Ability to Down-Modulate the CD4 Receptor, "Mol. Pharmacol. 63:203-210 Vermeire, K. et al. (October 2002), "CADA Inhibits Human Immunodeficiency Virus and Human Herpesvirus 7 Replication by Down-modulation of the Cellular CD4 Receptor," Virology 302: 342-353 Zhang, Y. et al. (1999), "Selective activity of various antiviral

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here or "x" if English language Translation is attached.